Quick summary
Dulaglutide is a once-weekly GLP-1 receptor agonist built from two GLP-1 analog chains fused to an IgG4 Fc fragment. It is FDA-approved as Trulicity for type 2 diabetes and has established cardiovascular risk reduction in the REWIND outcomes trial.
Overview
Dulaglutide is a once-weekly injectable GLP-1 receptor agonist developed by Eli Lilly and FDA-approved in 2014. Structurally, it consists of two GLP-1 analog chains covalently linked to a modified human IgG4 Fc fragment, enabling its extended half-life. The REWIND cardiovascular outcomes trial established dulaglutide as one of the few GLP-1 agents with demonstrated reduction in major adverse cardiovascular events.
Mechanism of action
Dulaglutide activates GLP-1 receptors on pancreatic beta cells in a glucose-dependent manner, stimulating insulin secretion via cAMP/PKA signaling while suppressing glucagon release from alpha cells. The fusion to IgG4 Fc dramatically extends the half-life to approximately 90 hours by reducing renal clearance and conferring resistance to DPP-4 degradation. Gastric emptying is slowed, reducing postprandial glucose excursions. Central GLP-1R signaling in the hypothalamus and area postrema suppresses appetite and promotes satiety. The Fc domain also prevents neonatal Fc receptor (FcRn)-mediated degradation, enabling once-weekly subcutaneous dosing with stable plasma concentrations.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| type 2 diabetes glycemic control | subcutaneous | 0.75–1.5 mg | once weekly | Start at 0.75 mg once weekly. May increase to 1.5 mg once weekly for additional glycemic control after at least 4 weeks. Some patients titrate to 3 mg or 4.5 mg (higher approved doses). |
| cardiovascular risk reduction | subcutaneous | 0.75–1.5 mg | once weekly | Same dosing as glycemic control. REWIND trial used 1.5 mg/week. Inject on same day each week regardless of meals. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
The AWARD phase 3 program across 8 trials demonstrated HbA1c reductions of 0.7–1.6% and weight loss of 1.5–3.0 kg vs. placebo. The landmark REWIND trial (9,901 patients, median 5.4 years follow-up) showed a 12% reduction in major adverse cardiovascular events (MACE: CV death, nonfatal MI, nonfatal stroke) vs. placebo in patients with established or high CV risk. This MACE benefit was observed even in patients without prior cardiovascular disease at baseline — a distinguishing feature among GLP-1 agents.[1][2][3][4]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Dulaglutide for synergistic effects.
Legal status
FDA-approved September 2014. Indicated for type 2 diabetes mellitus glycemic control and cardiovascular risk reduction in adults with established cardiovascular disease or multiple CV risk factors. Available as prefilled auto-injector pen. Patent protection ongoing; biosimilar entry expected mid-2020s.
Sourcing & access
Prescription required
Dulaglutide is an FDA-approved prescription medication available through licensed healthcare providers, telehealth platforms, and 503A/503B compounding pharmacies.
Frequently asked questions
Dulaglutide is a once-weekly injectable GLP-1 receptor agonist developed by Eli Lilly and sold as Trulicity. Structurally it consists of two GLP-1 analog chains covalently linked to a modified human IgG4 Fc fragment.
Dulaglutide activates GLP-1 receptors on pancreatic beta cells in a glucose-dependent manner, stimulating insulin secretion while suppressing glucagon release. It slows gastric emptying and suppresses appetite via central GLP-1 receptor signaling in the hypothalamus and area postrema.
Yes — dulaglutide was FDA-approved in September 2014 for glycemic control in type 2 diabetes, and is also indicated for cardiovascular risk reduction in adults with established cardiovascular disease or multiple CV risk factors.
Patients typically start at 0.75 mg once weekly subcutaneously and may increase to 1.5 mg weekly after at least 4 weeks. Some patients titrate to higher approved doses of 3 mg or 4.5 mg weekly for additional glycemic control.
Yes — the REWIND trial (9,901 patients, median 5.4 years follow-up) showed a 12% reduction in major adverse cardiovascular events versus placebo. The MACE benefit was observed even in patients without prior cardiovascular disease at baseline.
Dulaglutide has a half-life of approximately 90 hours, or about 5 days. Its covalent fusion to an IgG4 Fc fragment dramatically reduces renal clearance and confers resistance to DPP-4 degradation. The Fc domain also evades neonatal Fc receptor recycling, enabling stable plasma concentrations across once-weekly subcutaneous dosing intervals.
The most common side effects are gastrointestinal: nausea (usually resolving within weeks), diarrhea, vomiting, and abdominal pain. Less common effects include decreased appetite, fatigue, injection site reactions, rare pancreatitis, and a class contraindication in patients with a personal or family history of medullary thyroid carcinoma or MEN2.
Research references
- Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)PubMed
- Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)PubMed
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialPubMed
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trialPubMed